Madrigal's 15-minute chart has recently triggered a MACD Death Cross and KDJ Death Cross at 08/28/2025 15:15. This technical indicator suggests that the stock price is poised to continue declining, as the momentum has shifted towards a downward trend with a potential for further decreases.
Inventiva Inc. (NASDAQ: IVA) saw its stock climb by approximately 15% on Wednesday, following Piper Sandler's launch of its coverage with an Overweight recommendation. The analyst firm cited Inventiva's lead candidate, lanifibranor, which is targeted at metabolic dysfunction-associated steatohepatitis (MASH), a liver condition [1].
Yasmeen Rahimi, the analyst at Piper Sandler, set a $26 per share target for IVA. Rahimi highlighted that the Phase 3 NATiV3 trial for lanifibranor is expected to provide a topline readout, which could potentially be a stock-moving event. Additionally, Rahimi pointed out a significant valuation gap between Inventiva and Madrigal Pharmaceuticals (MDGL), whose lead candidate, Rezdiffra, became the first FDA-approved MASH therapy in 2024. The valuation disconnect presents a compelling buying opportunity for IVA, as its oral asset is already de-risked for the probability of success [1].
Meanwhile, Madrigal's stock has recently triggered a MACD Death Cross and KDJ Death Cross on August 28, 2025, at 15:15. These technical indicators suggest that the stock price is poised to continue declining, as the momentum has shifted towards a downward trend with potential for further decreases.
References:
[1] https://seekingalpha.com/news/4489664-inventiva-stock-surges-piper-sandler-bullish-view
Comments
No comments yet